{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:46Z","timestamp":1788949006909,"version":"build-2803163510"},"reference-count":19,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with doxorubicin, vinblastine, and dacarbazine (AVD; A+AVD) exhibited superior modified progression-free survival (PFS) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for frontline treatment of patients with stage III\/IV classical Hodgkin lymphoma (cHL). Maturing positron emission tomography (PET)-adapted trial data highlight potential limitations of PET-adapted approaches, including toxicities with dose intensification and higher-than-expected relapse rates in PET scan after cycle 2 (PET2)-negative (PET2\u2212) patients. We present an update of the ECHELON-1 study, including an exploratory analysis of 3-year PFS per investigator. A total of 1334 patients with stage III or IV cHL were randomized 1:1 to receive 6 cycles of A+AVD (n = 664) or ABVD (n = 670). Interim PET2 was required. At median follow-up of 37 months, 3-year PFS rates were 83.1% with A+AVD and 76.0% with ABVD; 3-year PFS rates in PET2\u2212 patients aged &amp;lt;60 years were 87.2% vs 81.0%, respectively. A beneficial trend in PET2+ patients aged &amp;lt;60 years on A+AVD was also observed, with a 3-year PFS rate of 69.2% vs 54.7% with ABVD. The benefit of A+AVD in the intent-to-treat population appeared independent of disease stage and prognostic risk factors. Upon continued follow-up, 78% of patients with peripheral neuropathy on A+AVD had either complete resolution or improvement compared with 83% on ABVD. These data highlight that A+AVD provides a durable efficacy benefit compared with ABVD for frontline stage III\/IV cHL, consistent across key subgroups regardless of patient status at PET2, without need for treatment intensification or bleomycin exposure. This trial was registered at www.clinicaltrials.gov as #NCT01712490 (EudraCT no. 2011-005450-60).<\/jats:p>","DOI":"10.1182\/blood.2019003127","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T12:00:22Z","timestamp":1579176022000},"page":"735-742","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":104,"title":["Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study"],"prefix":"10.1182","volume":"135","author":[{"given":"David J.","family":"Straus","sequence":"first","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-4125","authenticated-orcid":false,"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"first","affiliation":[{"name":"Department of Hematology, Jagiellonian University Medical College, Krakow, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Alekseev","sequence":"first","affiliation":[{"name":"N. N. Petrov Scientific Research Institute of Oncology, St. Petersburg, Russian Federation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"first","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"first","affiliation":[{"name":"Department of Advanced Biomedical Science, Federico II University Hospital, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Maranda","sequence":"first","affiliation":[{"name":"Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"first","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Smolewski","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada;"},{"name":"Department of Medical Oncology, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-2674","authenticated-orcid":false,"given":"Jan","family":"Walewski","sequence":"first","affiliation":[{"name":"Department of Lymphoid Malignancy, The Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"first","affiliation":[{"name":"Department of Medicine, Graduate School of Medicine, The University of Tennessee, Knoxville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"Institute of Hematology Seragnoli, University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-1741","authenticated-orcid":false,"given":"Martin","family":"Hutchings","sequence":"first","affiliation":[{"name":"Department of Hematology, Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada;"},{"name":"Department of Medical Oncology, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Manchester, Manchester, United Kingdom;"},{"name":"Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Banner MD Anderson Cancer Center, Gilbert, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"first","affiliation":[{"name":"Department of Medicine\/Oncology, Stanford Cancer Institute, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"first","affiliation":[{"name":"Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Miao","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals Company Limited;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Liu","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceuticals Company Limited;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Fenton","sequence":"first","affiliation":[{"name":"Seattle Genetics, Inc, Bothell, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"first","affiliation":[{"name":"Seattle Genetics, Inc, Bothell, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"first","affiliation":[{"name":"Research and Clinical Innovation, Antoine-Lacassagne Cancer Centre, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2020030512010928100_B1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"2020030512010928100_B2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020030512010928100_B3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020030512010928100_B4","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score \u2265 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020030512010928100_B5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2020030512010928100_B6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020030512010928100_B7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood-2018-99-113034","article-title":"Long-term follow-up of SWOG S0816: response-adapted therapy for stage III\/IV Hodgkin lymphoma demonstrates limitations of PET-adapted approach [abstract]","volume":"132","author":"Stephens","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2020030512010928100_B8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2020030512010928100_B9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020030512010928100_B10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2020030512010928100_B11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020030512010928100_B12","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2020030512010928100_B13","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)\n          . MedDRA: medical dictionary for regulatory activities. meddra.org. Accessed 9 October 2019."},{"key":"2020030512010928100_B14","volume-title":"Common Terminology Criteria for Adverse Events. Vol. 4","author":"Cancer Therapy Evaluation Program","year":"2010"},{"issue":"23","key":"2020030512010928100_B15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020030512010928100_B16","article-title":"Incidence and predictors of pulmonary events among patients with Hodgkin lymphoma treated with bleomycin in the US Department of Defense Healthcare System","volume":"7","author":"Fox","year":"2018","journal-title":"Chemotherapy"},{"issue":"10","key":"2020030512010928100_B17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","article-title":"Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Eichenauer","year":"2017","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2020030512010928100_B18","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-99-112907","article-title":"Brentuximab vedotin with chemotherapy in adolescents and young adults (AYA) with stage III or IV Hodgkin lymphoma: a subgroup analysis from the phase 3 ECHELON-1 study [abstract]","volume":"132","author":"Crosswell","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020030512010928100_B19","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2018-99-112178","article-title":"Older patients with previously untreated classical Hodgkin lymphoma: a detailed analysis from the phase 3 ECHELON-1 study [abstract]","volume":"132","author":"Evens","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/735\/1717860\/bloodbld2019003127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/10\/735\/1717860\/bloodbld2019003127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T12:01:17Z","timestamp":1583409677000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/10\/735\/431031\/Brentuximab-vedotin-with-chemotherapy-for-stage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,3,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003127","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}